Cefcapene pivoxil

Drug Profile

Cefcapene pivoxil

Alternative Names: Flomox; S 1108

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Shionogi
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections; Gram-negative infections; Gram-positive infections; Ophthalmic infections; Otorhinolaryngological infections; Respiratory tract infections; Skin and soft tissue infections; Urinary tract infections

Most Recent Events

  • 30 Nov 2008 Launched for Bacterial infections in Japan (PO)
  • 25 Nov 2008 Registered for Bacterial infections in Japan (PO, Granules)
  • 21 Aug 2000 Japan's Ministry of Health has requested Shionogi to strength label warnings on cefcapene to include jaundice and reduced platelet count
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top